Regulatory Edge RXQ is an FDA-registered 503B outsourcing facility with ISO 5 manufacturing, aligning with stringent federal and state requirements. This positions the company as a compliant, reliable partner for hospitals and ambulatory clinics seeking outsourced sterile compounding, enabling sales teams to target risk-averse networks and pursue contract opportunities focused on compliance.

Growth Funding Backed by the Ohio Innovation Fund and Advantage Capital, RXQ has demonstrated access to growth capital and a strategy to expand in Southern Ohio. This financing backdrop can be leveraged to approach regional health systems and larger national groups seeking scalable capacity to meet demand.

Market Expansion As a 503B outsourcing facility serving physician offices and hospitals nationwide, RXQ can capitalize on the growing trend of outsourced sterile compounding by offering a controlled, compliant supply chain and rigorous SOPs that reduce risk for customers.

Competitive Position RXQ's emphasis on stringent procedural manuals, regulatory engagement, and a safety-forward operating model provides a differentiator in a market dominated by larger players, supporting targeted wins with regional health systems and hospital networks.

Partnership Ecosystem Strategic ties to regulators, the Ohio Innovation Fund, and academia-backed capital create an ecosystem for joint programs and referrals. Sales can leverage these connections to access new hospital clients and expand channels through venture-backed partnerships.